U.S. Markets open in 1 hr 56 mins

Oramed Pharmaceuticals Inc. (ORMP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
9.37+0.46 (+5.16%)
At close: 4:00PM EST

9.90 +0.53 (5.66%)
Pre-Market: 6:46AM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close8.91
Open9.00
Bid9.58 x 900
Ask0.00 x 2200
Day's Range8.98 - 9.59
52 Week Range2.40 - 11.71
Volume272,691
Avg. Volume954,936
Market Cap275.201M
Beta (5Y Monthly)1.77
PE Ratio (TTM)N/A
EPS (TTM)-0.66
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.83
  • Oramed Issues Letter to Shareholders
    PR Newswire

    Oramed Issues Letter to Shareholders

    Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery technology, is pleased to provide the following Letter to Shareholders from Chief Executive Officer Nadav Kidron.

  • Oramed Doses Patients Across Multiple Sites in Phase 3 Oral Insulin Study
    PR Newswire

    Oramed Doses Patients Across Multiple Sites in Phase 3 Oral Insulin Study

    Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery, announced today that randomization of patients in its first Phase 3 study of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes (T2D) is under way. The study is being conducted in accordance with U.S. Food and Drug Administration (FDA) approved protocols.

  • We're Hopeful That Oramed Pharmaceuticals (NASDAQ:ORMP) Will Use Its Cash Wisely
    Simply Wall St.

    We're Hopeful That Oramed Pharmaceuticals (NASDAQ:ORMP) Will Use Its Cash Wisely

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...